Research
Mixed
Combining SGLT2 inhibitors with GLP-1 receptor agonists results in greater weight loss and HbA1c reduction than using either drug alone.
If one medication isn't enough to control your blood sugar and weight, ask about combining an SGLT2 inhibitor with a GLP-1 agonist. Studies show this combo leads to more weight loss (around 3.4 kg in trials) and better blood sugar control than using either drug alone.
GoodSupportsHIGH confidence
the results of the DURATION 8 study showed that a combination of dapagliflozin (an SGLT2i) once daily and exenatide (a GLP-1 RA) once weekly on a background of metformin treatment resulted in a 2% reduction in HbA1c and a weight loss of 3.4 kg after 28 weeks of administration; importantly, these beneficial changes were greater following combined therapy than when these drugs were used in monotherapy [24].
Why this rating
Based on a specific Phase 3 RCT (DURATION 8) cited.
Source
Medication use for the treatment of diabetes in obese individuals
John Wilding · Diabetologia · 2017
DOI 10.1007/s00125-017-4288-1
narrative_reviewCited 43×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) promote weight loss in obese individuals with type 2 diabetes, whereas sulfonylureas, thiazolidinediones, and insulin typically cause weight gain.Good
- Anti-obesity medications (Liraglutide 3mg, Lorcaserin, Naltrexone/Bupropion, Phentermine/Topiramate) are effective for weight loss in type 2 diabetes when used as adjuncts to lifestyle changes.Moderate
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →